Immediate Impact

2 by Nobel laureates 2 from Science/Nature 63 standout
Sub-graph 1 of 23

Citing Papers

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer
2022 Standout
2 intermediate papers

Works of Suprith Badarinath being referenced

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
2011
Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE)
2006

Author Peers

Author Last Decade Papers Cites
Suprith Badarinath 268 116 19 58 16 301
M. Kozloff 266 133 20 63 28 344
Stefania Di Girolamo 142 131 37 82 27 311
K.H. Link 162 65 45 69 15 288
Frank J. Panettiere 218 114 23 31 20 362
Wanda Honeycutt 268 115 44 53 20 361
Soetkin Vlassak 230 123 33 42 20 318
G.F. Samelis 239 155 24 35 23 357
Ludmila Katherine Martin 185 42 36 41 21 253
Dario Nicolella 225 156 45 32 16 328
Gary W. Jean 230 92 37 16 14 364

All Works

Loading papers...

Rankless by CCL
2026